|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C,
Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wakabayashi T, Natsume A, Mizusawa J,
Katayama H, Fukuda H, Sumi M, Nishikawa R, Narita Y, Muragaki Y,
Maruyama T, et al: JCOG0911 INTEGRA study: A randomized screening
phase II trial of interferonβ plus temozolomide in comparison with
temozolomide alone for newly diagnosed glioblastoma. J Neurooncol.
138:627–636. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012.
2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gupta PB, Fillmore CM, Jiang G, Shapira
SD, Tao K, Kuperwasser C and Lander ES: Stochastic state
transitions give rise to phenotypic equilibrium in populations of
cancer cells. Cell. 146:633–644. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Natsume A, Ito M, Katsushima K, Ohka F,
Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I,
et al: Chromatin regulator PRC2 is a key regulator of epigenetic
plasticity in glioblastoma. Cancer Res. 73:4559–4570.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yamamuro S, Sano E, Okamoto Y, Ochiai Y,
Ohta T, Ogino A, Natsume A, Wakabayashi T, Ueda T, Hara H, et al:
Antitumorigenic effect of interferon-β by inhibition of
undifferentiated glioblastoma cells. Int. J Oncol. 47:1647–1654.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ozawa Y, Yamamuro S, Sano E, Tatsuoka J,
Hanashima Y, Yoshimura S, Sumi K, Hara H, Nakayama T, Suzuki Y and
Yoshino A: Indoleamine 2,3-dioxygenase 1 is highly expressed in
glioma stem cells. Biochem Biophys Res Commun. 524:723–729.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yamamuro S, Okamoto Y, Sano E, Ochiai Y,
Ogino A, Ohta T, Hara H, Ueda T, Nakayama T, Yoshino A and Katayama
Y: Characterization of glioma stem-like cells from human
glioblastomas. Int. J Oncol. 47:91–96. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hanihara M, Kawataki T, Oh-Oka K, Mitsuka
K, Nakao A and Kinouchi H: Synergistic antitumor effect with
indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine
glioma model. J Neurosurg. 124:1594–1601. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hosseinalizadeh H, Mahmoodpour M, Samadani
AA and Roudkenar MH: The immunosuppressive role of indoleamine 2,
3-dioxygenase in glioblastoma: Mechanism of action and
immunotherapeutic strategies. Med Oncol. 39(130)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Uyttenhove C, Pilotte L, Théate I,
Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ:
Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.
9:1269–1274. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Munn DH and Mellor AL: IDO in the tumor
microenvironment: Inflammation, counter-regulation, and tolerance.
Trends Immunol. 37:193–207. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jacquerie A, Hoeben A, Eekers DBP, Postma
AA, Vanmechelen M, de Smet F, Ackermans L, Anten M, Severens K,
Hausen AZ, et al: Prognostic relevance of high expression of
kynurenine pathway markers in glioblastoma. Sci Rep.
14(14975)2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kesarwani P, Prabhu A, Kant S, Kumar P,
Graham SF, Buelow KL, Wilson GD, Miller CR and Chinnaiyan P:
Tryptophan metabolism contributes to radiation-induced immune
checkpoint reactivation in glioblastoma. Clin. Cancer Res.
24:3632–3643. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mitsuka K, Kawataki T, Satoh E, Asahara T,
Horikoshi T and Kinouchi H: Expression of indoleamine
2,3-dioxygenase and correlation with pathological malignancy in
gliomas. Neurosurgery. 72:1031–1039. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yuki K, Natsume A, Yokoyama H, Kondo Y,
Ohno M, Kato T, Chansakul P, Ito M, Kim SU and Wakabayashi T:
Induction of oligodendrogenesis in glioblastoma-initiating cells by
IFN-mediated activation of STAT3 signaling. Cancer Lett. 284:71–79.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nishide T, Yamamuro S, Sano E, Aida Y,
Nara K, Yazawa G, Ozawa Y and Yoshino A: Synergistic effect of
perampanel with temozolomide on glioblastoma cells in vivo.
Heliyon. 11(e43167)2025.
|
|
19
|
Wainwright DA, Chang AL, Dey M,
Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang
L, et al: Durable therapeutic efficacy utilizing combinatorial
blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Clin Cancer Res. 20:5290–5301. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hoshi M, Saito K, Hara A, Taguchi A,
Ohtaki H, Tanaka R, Fujigaki H, Osawa Y, Takemura M, Matsunami H,
et al: The absence of IDO upregulates type I IFN production,
resulting in suppression of viral replication in the
retrovirus-infected mouse. J Immunol. 185:3305–3312.
2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Caja L, Tzavlaki K, Dadras MS, Tan EJ,
Hatem G, Maturi NP, Morén A, Wik L, Watanabe Y, Savary K, et al:
Snail regulates BMP and TGFβ pathways to control the
differentiation status of glioma-initiating cells. Oncogene.
37:2515–2531. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jin X, Jin X, Kim LY, Dixit D, Jeon HY,
Kim EJ, Kim JK, Lee SY, Yin J, Rich JN and Kim H: Inhibition of
ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to
differentiation therapy. Clin. Cancer Res. 24:383–394.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sato A, Sunayama J, Okada M, Watanabe E,
Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T and
Kitanaka C: Glioma-initiating cell elimination by metformin
activation of FOXO3 via AMPK. Stem Cells Transl Med. 1:811–824.
2012.PubMed/NCBI View Article : Google Scholar
|
